Evotec SE (Evotec SE) Net Margin %

: -19.85% (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Evotec SE's Net Income for the three months ended in Sep. 2023 was $-41.6 Mil. Evotec SE's Revenue for the three months ended in Sep. 2023 was $209.5 Mil. Therefore, Evotec SE's net margin for the quarter that ended in Sep. 2023 was -19.85%.

The historical rank and industry rank for Evotec SE's Net Margin % or its related term are showing as below:

EVO' s Net Margin % Range Over the Past 10 Years
Min: -29.59 Med: 8.73 Max: 34.87
Current: -13.35

EVO's Net Margin % is ranked worse than
70.56% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 3.77 vs EVO: -13.35

Evotec SE Net Margin % Historical Data

The historical data trend for Evotec SE's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Margin %

Get a 7-Day Free Trial

22.42

8.55

1.25

34.87

-23.38

Evotec SE Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23
Net Margin %	Get a 7-Day Free Trial															-16.22	-27.19	-11.30	-8.77	-19.85

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evotec SE Net Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Net Margin % distribution charts can be found below:

* The bar in red indicates where Evotec SE's Net Margin % falls into.

Evotec SE Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Evotec SE's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-186.075	/	796.025
	=	-23.38 %

Evotec SE's Net Margin for the quarter that ended in Sep. 2023 is calculated as

Net Margin	=	Net Income (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-41.574	/	209.475
	=	-19.85 %

Evotec SE (NAS:EVO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Evotec SE Net Margin % Related Terms

Thank you for viewing the detailed overview of Evotec SE's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE (Evotec SE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (NAS:EVO) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

EVOTF:USA 1EVT:Italy EVTd:UK 0IRF:UK EVT:Germany EVT:Germany EVT:Germany EVT:Germany EVTA:Germany EVT:Austria

Address

Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419

Website

https://www.evotec.com

Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.